p38 a-specific mapk inhibition (Merck & Co)
Structured Review
P38 A Specific Mapk Inhibition, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p38+a-specific+mapk+inhibition/p38map+sb203580/pm16275622-39-12-18
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: Blockade of p38 map kinase inhibits complement-induced acute lung injury in a murine model. Article Snippet: Features of acute lung injury include neutrophil influx and increased vascular permeability with resultant pulmonary edema.. Inhibition of p38 mitogen-activated protein kinase (MAPK) in in vivo models of endotoxin-induced inflammation results in reduction of organ injury as well as symptomatic relief.. In this study, mice received an oral dose (100 mg/kg) of the p38 MAPK inhibitor, SB203580, followed by intratracheal instillation of an agent of complement origin, C5a des arg, at a concentration (10 Ag) that induced acute lung injury. |
